Evaluation of Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in the Pathogenesis of Systemic Lupus Erythematosus

What this Trial Is About

This research aims to explore the role of certain autoantibodies in patients with active Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease that causes inflammation and tissue damage due to immune system dysfunction. The study focuses on autoantibodies targeting proteins involved in the classical pathway of complement activation (C1q and C1s) and the multifunctional protein HMGB1, and how these antibodies may affect disease mechanisms beyond the known pathways. Understanding these interactions may provide insight into the disease process in SLE. Participants' blood serum will be analyzed to purify and identify autoantibodies against C1s, HMGB1, and C1q. The study will evaluate the effects of these autoantibodies on protein interactions and activities, such as the formation of protein complexes and receptor binding relevant to the immune response. This pilot study involves 30 patients with active lupus and uses biological analyses of proteins and antibodies to investigate these molecular targets. Participants will contribute a single blood sample during one visit, which will be used to quantify the autoantibodies and study their functional impact. Researchers will measure the levels of antibodies and assess their effects on protein activities related to the complement system and receptor binding. The study does not involve treatment administration and focuses on laboratory evaluations of collected samples. The overall participation is limited to this one-time visit with no additional treatment or follow-up visits required.

Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)